Targeting sarcomas: Novel biological agents and future perspectives

Devalingam Mahalingam, Alain Mita, Kamalesh Sankhala, Ronan Swords, Kevin Kelly, Francis Giles, Monica M. Mita

Research output: Contribution to journalReview article

20 Scopus citations

Abstract

Sarcomas are a group of heterogeneous tumors that arise from mesenchymal tissue and account for approximately 1% of all adult solid malignancies diagnosed, although its incidence approaches 20% in pediatric cancers. Characterization of molecular abnormalities in patients with sarcomas, in particular the up-regulation of the receptor tyrosine kinase and the PI3K-AKT-mTOR pathway, loss or deletions of retinoblastoma (Rb) and p53 gene, increased VEGF expression and angiogenesis, dysregulation of apoptosis through Bcl-2 overexpression, along with oncogene mutations and activations, such as c-KIT in Gastrointestinal stromal tumors (GISTs), makes treatment with novel biological therapies a promising option. This review focuses on the molecular heterogeneity of soft tissue and bone sarcomas, novel biological therapies currently in clinical trials to target the various molecular pathways, and the potential biological agents in preclinical and early clinical development.

Original languageEnglish (US)
Pages (from-to)937-949
Number of pages13
JournalCurrent drug targets
Volume10
Issue number10
DOIs
StatePublished - Nov 26 2009

Keywords

  • AKT
  • Apoptosis
  • IGF-1R
  • mTOR
  • Ras
  • Sarcoma
  • VEGF and targeted therapy

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Fingerprint Dive into the research topics of 'Targeting sarcomas: Novel biological agents and future perspectives'. Together they form a unique fingerprint.

  • Cite this

    Mahalingam, D., Mita, A., Sankhala, K., Swords, R., Kelly, K., Giles, F., & Mita, M. M. (2009). Targeting sarcomas: Novel biological agents and future perspectives. Current drug targets, 10(10), 937-949. https://doi.org/10.2174/138945009789577990